FDA Approved (Rx) / OTC (low dose)Oral / IV · Mitochondrial

Methylene Blue

MB — Mitochondrial Electron Carrier & Cognitive Enhancer

Half-life
~5-6 hours
Route
Oral or IV
Typical dose
0.5–4 mg/kg low-dose cognitive; higher for medical
Reconstitutable
No — solution or tablet

What is Methylene Blue?

Methylene Blue is a synthetic compound with a 130-year history in medicine — originally used as an antimalarial dye, now FDA-approved for methemoglobinemia and vasoplegic syndrome. At low doses (0.5-4 mg/kg), it acts as an alternative mitochondrial electron carrier, improving ATP production efficiency. It has experienced a renaissance in biohacking for cognitive enhancement, neuroprotection, and anti-aging applications.

At low doses, Methylene Blue accepts electrons from NADH and transfers them to cytochrome c, bypassing dysfunctional sections of the mitochondrial electron transport chain and increasing ATP production. It also inhibits monoamine oxidase (MAO) and nitric oxide synthase at higher doses, and has powerful antioxidant activity through its redox cycling between oxidized (blue) and reduced (colorless) forms. It crosses the blood-brain barrier readily and concentrates in mitochondria-rich neurons.

Research Evidence

GoldMethemoglobinemia Treatment

FDA-approved first-line treatment. Strong efficacy and safety data for this specific indication.

SilverCognitive Enhancement

Human studies show low-dose methylene blue improves memory, attention, and cerebral blood flow. MRI studies demonstrate increased brain activation in memory regions.

SilverNeuroprotection

Multiple animal models show methylene blue protects against Alzheimer's, Parkinson's, and ischemia-related neuronal damage. Human trials for Alzheimer's (as LMTX) are ongoing.

Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary

Dosing Protocols

Cognitive dose
0.5–4 mg/kg
At low doses (0.5-4 mg/kg), MB acts as a mitochondrial electron donor. Above 10 mg/kg, effects reverse and it can impair cognition.
Practical dose
10–50 mg/day
Most biohacking protocols use 10-50mg/day. Start low — urine turns blue at any dose, saliva turns blue at higher doses.
Caution
MAO inhibition above 1 mg/kg
Above 1 mg/kg, MB has significant MAO inhibitory activity — can cause serotonin syndrome with SSRIs, SNRIs, or serotonergic compounds. Avoid combining with serotonergic drugs.
Staining
Blue urine and skin at doses
MB stains urine blue at virtually any dose. Higher doses stain saliva and skin. This is harmless but cosmetically notable.

Reconstitution / Preparation

This compound does not require reconstitution — it is available as an oral or pre-mixed formulation.

Frequently Asked Questions

Is Methylene Blue safe?

At low doses (0.5-4 mg/kg), methylene blue has an excellent safety profile based on 130 years of medical use. The primary concern is serotonin syndrome when combined with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol). People on any serotonergic medication should not use methylene blue. It is contraindicated in G6PD deficiency.

Does Methylene Blue really improve cognition?

Human evidence is promising. Resting-state fMRI studies show increased brain activation in memory regions with acute low-dose MB. Memory and attention tests show improvements in healthy subjects. The mechanism — improved mitochondrial electron transport in high-energy neurons — is biologically plausible. The cognitive effects appear to follow an inverted U dose-response curve: low doses improve cognition while high doses impair it.

References

  1. [1]Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45.
  2. [2]Bhatt S, Bhatt DL, Panza JA, et al. Methylene blue for vasoplegic syndrome in cardiac surgery. Ann Thorac Surg. 2016;101(3):1162-1164.
Disclaimer: This profile is for informational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before using any compound.

This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.

Share this article